Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

Internal Medicine Journal

Volumn 42, Issue 3, 2012, Pages 267-274

  Chan, A ^a   McGregor, S R ^a  

^a Mount Hospital   (Australia)

Author keywords

Breast cancer; HER2 neu; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; HEART DISEASES; HOSPITALS, COMMUNITY; HOSPITALS, PRIVATE; HUMANS; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; STROKE VOLUME; SURVIVAL ANALYSIS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; WESTERN AUSTRALIA;

EID: 84858738086     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02432.x     Document Type: Article

References (24)

1. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
2. Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L etal. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
3. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I etal. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
4. Romond E, Perez E, Bryant J, Suman V, Geyer C, Davidson N etal. Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
5. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M etal. BCIRG 006 - 1st Interim Analysis on Efficacy and Safety. San Antonio Breast Cancer Symposium 2005.
6. Wolff A, Hammond E, Schwartz J, Hagerty K, Allred C, Cote R etal. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
7. Slamon D, Clarke G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
8. Gusterson B, Gelber R, Goldhirsch A, Price K, Save-Soderborgh J, Anbazhagan R etal. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
9. Press M, Bernstein L, Thomas P, Meisner L, Zhou J, Ma Y etal. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-904.
10. Carlson R, Allred D, Anderson B, Burstein H, Bradford Carter W, Edge S etal. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: breast cancer V.1 2010. Available from URL:.
11. Olver I, Chirgwin J, Nowak A, Pendlebury S, Spillane A, Willsher P etal. HERG - Recommendations for Trastuzumab (Herceptin®) for treatment of HER2-positive breast cancer. National Breast and Ovarian Cancer Centre. 2007. Available from URL:.
12. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B etal. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003; 12: 92-8.
13. Ross J, Fletcher J, Linette G, Stec J, Clark E, Ayers M etal. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-25.
14. Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R etal. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 2008; 19: 1706-12.
15. Barron J, Cziraky M, Weisman T, Hicks D. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 2009; 14: 760-68.
16. Phillips K, Marshall D, Haas J, Elkin E, Liang S, Hassett M etal. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 2009; 115: 5166-74.
17. Tan-Chiu E, Yothers G, Romond E, Geyer C, Ewer M, Keefe D etal. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-19.
18. Withrow D, Verma S, Dent R, Ahmed S, Fralick J, Dranitsaris G etal. Trastuzumab-mediated cardiotoxicity in the non-trial setting: evaluation of patients receiving adjuvant trastuzumab at an academic centre. J Clin Oncol 2009; 27(15S): 11550.
19. Canney P, Linsday C, Wardley A, Jones A, Verril M, Todd R etal. Cardiac effects when using trial-derived monitoring protocols for adjuvant trastuzumab: results from a retrospective multicenter UK audit. J Clin Oncol 2009; 27(15S): 583.
20. Letarte N, Marcotte N, Michel M, Cossette B, Varin F, Froment D etal. Review of utilization of trastuzumab in the adjuvant treatment of breast cancer in four university teaching hospitals in Quebec, Canada. J Clin Oncol 2008; 26 (Suppl): 6615.
21. Shih V, Chan A, Chiang J, Teo C, Chen J, Wong Z etal. Cardiotoxicity risks of adjuvant trastuzumab in Asian breast cancer patients. J Clin Oncol 2009; 27(15S): 561.
22. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopolous S etal. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol 2007; 122: 195-201.
23. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20years of follow-up. N Engl J Med 1995; 332: 901-6.
24. Rafailidis P, Kakisi O, Vardakas K, Falagas M. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007; 109: 2182-9.